Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study).
Yu-Wei WangJie XuLikun MaHao HuHong-Wu ChenJing-Sheng HuaXiang-Yong KongDan LiLong-Wei LiJian-Yuan PanJiawei WuPublished in: BMJ open (2024)
ChiCTR2200066675.